ECOG-ACRIN EAY191

Primary Category:

Treatment Protocols

Disease Category:

Adjuvant Breast, Anal, Bladder, Brain, Brain Metastatic, Breast, Breast Metastatic, Carcinoid, Carcinoid Metastatic, Cervical, Cervical Metastatic, Cholangiocarcinoma, Colon, Colon Metastatic, Endometrial, Endometrial Metastatic, Esophageal, Esophageal Metastatic, Gallbladder, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Head and Neck Metastatic, Liver, Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic, Lung - Small Cell, Lung - Small Cell Extensive Stage, Lung - Small Cell Limited Stage, Melanoma, Mesothelioma, Metastatic Melanoma, Molecular Profiling, Neuroendocrine, Other, Ovarian, Ovarian Metastatic, Pancreatic, Pancreatic Metastatic, Prostate, Prostate Metastatic, Prostate Recurrent, Rectal, Rectal Metastatic, Renal, Renal Metastatic, Sarcoma, Skin, Small Bowel, Solid tumor or Hematologic Malignancy, Stomach, Stomach Metastatic, Thyroid, Uterine, Uterine Metastatic

Status:

Open

Molecular Analysis for Combination Therapy Choice (ComboMATCH)
A screening trial for EAY191-A3, EAY191-A6, EAY191-E4, EAY191-E5, EAY191-N2, EAY191-N4 and EAY191-S3.

NCT#05564377

Eligible for screening study DCP 001